News

GlaxoSmithKline’s Requip XL is said to be the first and only oral once-daily non-ergot dopamine agonist indicated for Parkinson’s disease. The product should be available in pharmacies in

The acquisition is based on the offer price of 135 pence in cash for each ClinPhone share. The offer price represents a premium of 86% to the ClinPhone

Mr Liao joined the company in March 2008, and had served in various capacities before being appointed to the role of CFO on May 7, 2008. Yukun Zhang,

In this study of heavily pretreated patients, 83 were eligible for response evaluation. An objective response was observed in 29% of patients, with 6% achieving a complete response

NuView Radiopharmaceuticals will act as exclusive agent for Positron’s brand of Pet, Spect and automated dose dispensing systems. Paul Crowe, CEO of NuView, said: “We’re very pleased to

The study, which began in North America in January, 2008 is evaluating the antiplatelet medicine CGT-2168, a combination of clopidogrel (currently marketed by Bristol-Myers Squibb and Sanofi-Aventis as

The results of this 500 patient study, which is taking place at specialist and general centres in the US and Canada, are expected in the first quarter of

In clinical trials with Soliris, paroxysmal nocturnal hemoglobinuria (PNH) patients experienced a substantial improvement in PNH-related fatigue independent of changes in their anemia. This improvement was larger than

The study showed Velcade-based therapy with melphalan and prednisone (VMP) achieves superior complete response rates which are significantly durable and may be prolonged with continued therapy after the